RESEARCH DIGEST // NONAPEPTIDE THYMIC HORMONE
Thymulin: the zinc-dependent thymic peptide, summarized from the published research record.
Nine amino acids. One zinc cofactor. Forty years of peer-reviewed literature on T-cell differentiation, immunosenescence, cytokine modulation, and analgesic activity. Indexed and cited here.
BACKGROUND
Thymulin (Serum Thymic Factor): Background and Discovery
Thymulin — historically called serum thymic factor, or FTS from the French facteur thymique sérique — was isolated and characterized in the early 1970s by Bach and Dardenne. It is a nonapeptide: nine amino acids in the sequence pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn. Molecular weight: 858.86 Da. CAS number: 63958-90-7.
pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-AsnThe defining feature is zinc dependency. Thymulin is biologically inactive without a bound zinc ion. The zinc-free form — apothymulin — circulates in serum but produces no immunological effect. Only the Zn-thymulin complex binds the thymulin receptor on T-lymphocyte precursors.[1]
Production is exclusive to thymic epithelial cells. No other tissue has been identified as a source.[22] Serum thymulin follows a circadian rhythm, with peak levels measured at approximately 1:00 a.m. in rodent models.[23][24]
The serum thymic factor literature spans more than four decades and multiple research groups — primarily the Bach/Dardenne group (France/Lebanon), the Reggiani/Goya group (Argentina), and the Novoselova/Lunin group (Russia). The findings are consistent: T-cell differentiation, cytokine modulation, and an age-related decline tied to both thymic involution and zinc insufficiency.
WHAT IS THYMULIN?
What Is Thymulin?
Thymulin is an endogenous nonapeptide hormone produced exclusively by thymic epithelial cells. It was originally described as serum thymic factor (FTS) in the 1970s. Biological activity depends on a 1:1 molar complex with zinc — the zinc-free apothymulin is immunologically inert.[1]
Regulatory note: As of the peer-reviewed literature, Thymulin has no FDA-approved therapeutic indication. It is studied as a research compound. No exogenous thymulin administration trials in humans have been published.
RESEARCH APPLICATIONS
What Is Thymulin Used For in Research?
Across the published record, Thymulin has been studied for:
- T-cell differentiation: Inducing surface expression of T-cell markers (Thy-1, Lyt-1, Lyt-2) on immature thymocytes and bone marrow precursor cells[4]
- Immune modulation: Suppressing pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IFN-gamma) while upregulating anti-inflammatory IL-10[12]
- Analgesic activity: Dose-dependent reduction of thermal hyperalgesia and inflammatory pain in rodent models[14][15]
- Neuroprotection: Inhibition of NF-kappaB nuclear translocation in hippocampal astrocytes[17]
- Immunosenescence research: Characterizing and partially reversing age-related thymic decline via zinc repletion and gene therapy approaches[7][21]
No approved human therapeutic indication exists.
See common questions answeredPRODUCTION SOURCE
Where Is Thymulin Produced?
Thymulin is produced by two distinct epithelial cell populations within the thymus gland.[22] Serum levels are detectable only when the peptide is zinc-bound — the zinc-free form is immunologically silent. Growth hormone, prolactin, and thyroid hormones stimulate thymulin production from thymic epithelium; thymulin reciprocally regulates anterior pituitary ACTH release, establishing a bidirectional neuroendocrine-immune axis.[24]
Production peaks in children aged 5–10 years. Measurable decline begins after puberty. By age 36, mean serum titres in a cross-sectional cohort of 93 healthy subjects dropped from a peak of 4.77 to 0.66.[6]
Read about age-related declineTHE EVIDENCE BASE
The Research Record at a Glance
The thymulin peptide literature includes:
- Zinc dependency — biochemically characterized 1982 (Dardenne et al., PNAS);[1] three-dimensional zinc-dependent epitope confirmed 1985[3]
- T-cell differentiation — synthetic FTS induced T-cell surface markers on human bone marrow precursor cells in vitro (Incefy et al., 1980)[4]
- Human zinc deficiency — serum thymulin activity restored by oral zinc supplementation in zinc-deficient human subjects (Prasad et al., 1988, Journal of Clinical Investigation)[5]
- Age-related decline — quantitative lifespan trajectory documented in 93 healthy humans across 80 years (Consolini et al., 2000)[6]
- Cytokine suppression — 15 µg/100g i.p. prevented plasma accumulation of five pro-inflammatory cytokines in LPS-challenged mice (Lunin et al., 2008)[12]
- Inflammatory pain — reduced thermal hyperalgesia and spinal microglial activation in CFA rat models (Nasseri et al., 2019)[14]
- Gene therapy — single intratracheal nanoparticle dose reversed key pathology of experimental allergic asthma within 20 days (Science Advances, 2020)[26]
For the full indexed findings, see the thymulin peptide research page.